Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.5400+0.1400 (+10.00%)
At close: 04:00PM EDT
1.4813 -0.06 (-3.81%)
After hours: 05:54PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    Rigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing Pact

    Rigel Pharmaceuticals Inc (NASDAQ: RIGL) and Forma Therapeutics Inc (NASDAQ: FMTX) entered into an exclusive, worldwide license agreement to develop, manufacture and commercialize olutasidenib. Olutasidenib is an oral, small molecule inhibitor of mIDH1 being investigated for relapsed/refractory acute myeloid leukemia (R/R AML) and other malignancies. The FDA has accepted Forma's marketing application for olutasidenib with the Prescription Drug User Fee Act target date of February 15, 2023. Relat

  • Zacks

    Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

    Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update

    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2022, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Advertisement
Advertisement